目的 探討銀丹心腦通軟膠囊聯(lián)合瑞舒伐他汀鈣片治療經(jīng)皮冠脈介入術(shù)（PCI）后急性心肌梗死的臨床療效。方法 選取2017年1月—2020年1月鶴壁市人民醫(yī)院收治的80例急性心肌梗死患者，根據(jù)信封法分為對(duì)照組和治療組，每組各40例。對(duì)照組口服瑞舒伐他汀鈣片，20 mg/次，1次/d。治療組患者在對(duì)照組治療的基礎(chǔ)上口服銀丹心腦通軟膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組患者臨床療效，比較兩組心功能、血脂情況。結(jié)果 治療后，對(duì)照組總有效率為70.00%，治療組總有效率為90.00%，治療組較對(duì)照組高（P<0.05）。治療后，兩組左心室射血分?jǐn)?shù)（LVEF）升高，左心室收縮末期內(nèi)徑（LVESD）、左心室舒張末期內(nèi)徑（LVEDD）下降（P<0.05），并且治療后治療組LVEF高于對(duì)照組，LVESD、LVEDD低于對(duì)照組（P<0.05）。治療后，兩組總膽固醇（TC）、低密度脂蛋白（LDL）、三酰甘油（TG）水平較治療前下降，高密度脂蛋白（HDL）水平較治療前升高（P<0.05），且治療組TC、LDL、TG水平低于對(duì)照組，HDL水平高于對(duì)照組（P<0.05）。治療后，兩組梗死面積、肌酸激酶同工酶（CK-MB）、乳酸脫氫酶（LDH）較治療前下降（P<0.05），且治療組梗死面積、CK-MB、LDH低于對(duì)照組（P<0.05）。結(jié)論 銀丹心腦通軟膠囊聯(lián)合瑞舒伐他汀鈣片可改善經(jīng)皮冠脈介入術(shù)后急性心肌梗死患者的心功能、血脂、心肌酶譜、梗死面積，藥物臨床療效值得肯定。

Objective To investigate the effect of Yindan Xinnaotong Soft Capsules combined with Rosuvastatin Calcium Tablets in treatment of acute myocardial infarction after percutaneous coronary intervention. Methods Patients (80 cases) with acute myocardial infarction after percutaneous coronary intervention in the People’s Hospital of Hebi from January 2017 to January 2020 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Yindan Xinnaotong Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and heart function and blood lipid were compared between two groups. Results After treatment, the total effective rate of the control group was 70.00%, and that of the treatment group was 90.00%, which was higher than that of the control group (P<0.05). After treatment, the LVEF in two groups were increased, but the LVESD and LVEDD in two groups were decreased (P<0.05). And the LVEF in the treatment group was higher than that in the control group, while the LVESD and LVEDD in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of TC, LDL, and TG in two groups were decreased, while the levels of HDL in two groups were increased (P<0.05). The levels of TC, LDL, and TG in the treatment group were lower than those in the control group, but the level of HDL in the treatment group was higher than that in the control group (P<0.05). After treatment, the infarct size, CK-MB, and LDH of two groups were decreased (P<0.05), and the infarct size, CK-MB, and LDH of the treatment group were lower than those of the control group (P<0.05). Conclusion Yindan Xinnaotong Soft Capsules combined with Rosuvastatin Calcium Tablets in treatment of acute myocardial infarction after percutaneous coronary intervention can improve the cardiac function, blood lipid, myocardial enzyme spectrum and infarct size, and the clinical efficacy of the drug is worthy of affirmation.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（201603117）